Imagine being trapped in a cycle where the very medication keeping you alive is slowly damaging your body. That's the reality for many with severe asthma who rely on oral steroids. But what if there was a way out? What if you could significantly reduce your steroid use and gain better control of your asthma? New research suggests this might be possible with tezepelumab.
Exciting findings from the WAYFINDER trial, unveiled at the American College of Chest Physicians (CHEST) 2025 Annual Meeting in Chicago, demonstrate the dual benefits of tezepelumab for severe, steroid-dependent asthma patients. The study revealed that nearly 90% of adult participants were able to decrease their daily oral corticosteroid (OCS) dose to 5 mg or less while simultaneously experiencing improved asthma control. And this is the part most people miss: the proportion of patients achieving well-controlled asthma skyrocketed from a mere 3% at the beginning of the study to almost 27% after 52 weeks of treatment! That's a nine-fold increase!
These results are a game-changer because prolonged use of oral corticosteroids comes with a laundry list of serious side effects. Think bone loss, metabolic problems like diabetes, and a weakened immune system, making you more susceptible to infections. For years, doctors have been searching for effective steroid-sparing strategies to alleviate these risks in severe asthma management. This study suggests tezepelumab could be a significant step in that direction.
So, how does tezepelumab work its magic? Unlike other asthma biologics that target specific inflammatory molecules downstream, tezepelumab takes a different approach. It's a human monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP). TSLP is an epithelial cytokine – essentially, a signaling protein released by cells lining the airways – that sits at the very top of the inflammatory cascade in asthma. By hitting this upstream target, tezepelumab simultaneously addresses multiple inflammatory pathways, offering a broader effect than biologics that only target, say, IgE or specific interleukins. You can think of it like cutting off the head of a hydra, rather than just dealing with individual heads.
Currently, tezepelumab is approved as an add-on maintenance therapy for individuals aged 12 and older with severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) whose asthma isn't adequately controlled by their existing treatments.
Diving Deeper into the WAYFINDER Trial
The WAYFINDER trial (NCT05274815), led by Dr. David Jackson from Guy's Hospital King's College London, was an open-label, single-arm, multicenter phase 3b study. This means that everyone in the trial received tezepelumab, and there was no placebo group for comparison. While this design has limitations, the dramatic improvements observed still provide compelling evidence of the drug's potential. The trial enrolled 298 adults with severe asthma who required daily oral corticosteroids (prednisone or prednisolone at doses of 5–40 mg) for at least three months prior to joining the study. Participants received a subcutaneous injection of 210 mg of tezepelumab every four weeks for a year.
The study involved a four-week induction phase, during which steroid doses remained stable, followed by a 48-week reduction and maintenance phase. Here's where it gets controversial... The steroid tapering process was carefully managed, with dose reductions limited to less than 5 mg per day. Crucially, adrenal function was closely monitored using morning cortisol tests and adrenocorticotropic hormone stimulation tests to prevent adrenal insufficiency, a potentially serious complication of steroid withdrawal. Some might argue that this cautious tapering approach could have influenced the results, as slower tapering may make it easier to reduce steroid doses without triggering asthma exacerbations.
Key Findings from WAYFINDER
Dr. Jackson reported that at the start of the trial, participants were taking an average of 10.8 mg of oral corticosteroids daily. By week 28, a remarkable 88.9% had reduced their dose to 5 mg or less per day, and this proportion remained stable at 89.9% through week 52. Even more impressive, 82.2% of those who achieved the lower maintenance dose did not experience a loss of asthma control at week 52, even after accounting for any systemic corticosteroid use related to adrenal insufficiency.
Beyond steroid reduction, tezepelumab also led to substantial improvements in asthma control. At baseline, a staggering 80.2% of participants had uncontrolled asthma. By week 52, this number plummeted to 34.9%. The Asthma Control Questionnaire-6 (ACQ-6) score, a measure of asthma symptom burden, improved significantly from an average of 2.6 at baseline to 1.5 at week 28 and 1.4 at week 52. These reductions are considered clinically meaningful, indicating a real improvement in patients' quality of life. By the end of the trial, nearly half (47.3%) of participants had achieved at least partially controlled asthma.
Out of the 298 participants who started the treatment, 273 completed the entire study, highlighting the tolerability of tezepelumab. The safety profile was consistent with what had been observed in previous clinical trials.
Tezepelumab: A History of Clinical Trials
Tezepelumab received FDA approval for severe asthma in patients 12 years and older back in 2021. However, the road to approval wasn't entirely smooth. Earlier trials, such as the SOURCE study, had mixed results. SOURCE, for example, didn't meet its primary endpoint of significant OCS reduction without compromising asthma control. But here's where it gets controversial... A subgroup analysis revealed that tezepelumab was effective in patients with higher baseline eosinophil counts (≥150 cells/μL). This suggests that tezepelumab might be more effective in certain subtypes of severe asthma.
The subsequent DESTINATION extension trial, which followed patients for a total of 104 weeks, provided more encouraging data. This trial showed that 66.7% of tezepelumab-treated patients were able to discontinue OCS use compared to just 46.9% in the placebo group. This evidence ultimately laid the groundwork for the more robust WAYFINDER study.
As the landscape of biologics for severe asthma continues to expand, tezepelumab's unique mechanism of action – targeting TSLP – positions it as a valuable option, particularly for patients with persistent inflammation despite being on maximal conventional therapies. The WAYFINDER findings strongly support its role in personalized respiratory care strategies aimed at both modifying the disease and reducing the harmful effects of long-term steroid use.
Now, it's your turn!
What are your thoughts on these findings? Do you think tezepelumab represents a significant advancement in the treatment of severe, steroid-dependent asthma? Could it potentially change the way we manage this challenging condition? Share your opinions and experiences in the comments below. Let's discuss the potential benefits and limitations of this novel therapy.
References
Tezepelumab significantly improves severe asthma control. News release. American Medical Journal. October 30, 2025. Accessed November 4, 2025. https://www.emjreviews.com/en-us/amj/respiratory/news/tezepelumab-significantly-improves-severe-asthma-control/
Study to evaluate efficacy and safety of tezepelumab in reducing oral corticosteroid use in adult patients with severe asthma (WAYFINDER). ClinicalTrials.gov identifier: NCT05274815. Updated October 23, 2024. Accessed November 4, 2025. https://clinicaltrials.gov/study/NCT05274815
Jackson DJ, Lugogo N, Gurnell M, et al. Tezepelumab reduces and eliminates OCS use in OCS-dependent patients with severe asthma: primary results from the phase 3b WAYFINDER study. Am J Respir Crit Care Med. 2025;211:A5231. doi:10.1164/ajrccm.2025.211.Abstracts.A5231
Tezspire (tezepelumab-ekko). Prescribing information; Astra Zeneca; 2025. Accessed November 4, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761224s000lbl.pdf
